Literature DB >> 2438338

Monoclonal antibodies to human recombinant interleukin 1 (IL 1)beta: quantitation of IL 1 beta and inhibition of biological activity.

J S Kenney, M P Masada, E M Eugui, B M Delustro, M A Mulkins, A C Allison.   

Abstract

Monoclonal antibodies (McAb) were developed to the Mr 17,500 form of human recombinant interleukin 1, IL 1 beta. Four McAb have been identified that inhibit the biological activity of IL 1 beta. McAb H34 and H67, at 1 microgram/ml (6 X 10(-9) M), completely inhibit the capacity of 1 ng/ml (6 X 10(-11) M) recombinant IL 1 beta to stimulate the proliferation of murine thymocytes or human fibroblasts in vitro. McAb H6 and H21 are approximately 10-fold less potent, and completely inhibit IL 1 beta activity at 10 micrograms/ml (6 X 10(-8) M) in both assays. The McAb do not have a significant effect on the biological activity of human recombinant IL 1 alpha in either assay. These McAb block the binding of recombinant [125I]IL 1 beta to IL 1 receptors on mouse 3T3 fibroblasts and have affinity constants for IL 1 beta in the range of 10(9) to 10(10) liters/mol. Competition studies suggest that two nonoverlapping epitopes on the IL 1 beta molecule are recognized by the McAb. H6 and H34 recognize one epitope, and H21 and H67 another. McAb H6 and H67 have been used together in a two-site ELISA to detect IL 1 beta. The sensitivity of the ELISA, which is 15 pg/ml (0.86 pM), approaches the limit of sensitivity of the thymocyte proliferation assay. The ELISA and thymocyte proliferation assay were used to quantitate IL 1 beta in E. coli LPS-stimulated human monocyte culture supernatants (HMCS). The level of IL 1 beta detected by ELISA in culture supernatants from eight donors ranged from 1.7 to 5.6 ng/ml, with a mean value of approximately 3 ng/ml. By comparison, the thymocyte proliferation assay gave levels of IL 1 in HMCS that were eight fold higher when quantitated by using recombinant IL 1 beta as a standard. This discrepancy with the bioassay used was reflected by the three fold higher maximum stimulation of thymocyte proliferation by HMCS as compared with recombinant IL 1 alpha or IL 1 beta, and only 45% inhibition of HMCS IL 1 activity by McAb. Thus, factors other than IL 1 beta account for the IL 1-like activity in monocyte culture supernatant as measured by the bioassay. The ILB1 McAb and ELISA allow for the first time-sensitive, accurate, and convenient quantitation of IL 1 beta levels in biological fluids or specimens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2438338

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2.

Authors:  P H Hart; G F Vitti; D R Burgess; G A Whitty; D S Piccoli; J A Hamilton
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

2.  In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.

Authors:  J M Reimund; S Dumont; C D Muller; J S Kenney; M Kedinger; R Baumann; P Poindron; B Duclos
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

3.  Lymphoid hyperplasia in transgenic mice over-expressing a secreted form of the human interleukin-1beta gene product.

Authors:  O Björkdahl; P Akerblad; A Gjörloff-Wingren; T Leanderson; M Dohlsten
Journal:  Immunology       Date:  1999-01       Impact factor: 7.397

4.  Effect of hypertriglyceridemia on endotoxin responsiveness in humans.

Authors:  T van der Poll; C C Braxton; S M Coyle; M A Boermeester; J C Wang; P M Jansen; W J Montegut; S E Calvano; C E Hack; S F Lowry
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans.

Authors:  Y M Fong; M A Marano; L L Moldawer; H Wei; S E Calvano; J S Kenney; A C Allison; A Cerami; G T Shires; S F Lowry
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

6.  Oxygen radical scavengers selectively inhibit interleukin 8 production in human whole blood.

Authors:  L E DeForge; J C Fantone; J S Kenney; D G Remick
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

7.  Amniotic fluid interleukin 6 in preterm labor. Association with infection.

Authors:  R Romero; C Avila; U Santhanam; P B Sehgal
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

8.  Interleukin-1 receptor antagonist protein inhibits interleukin-8 expression in lipopolysaccharide-stimulated human whole blood.

Authors:  L E DeForge; D E Tracey; J S Kenney; D G Remick
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

9.  Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.

Authors:  E Fischer; M A Marano; K J Van Zee; C S Rock; A S Hawes; W A Thompson; L DeForge; J S Kenney; D G Remick; D C Bloedow
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

10.  Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone.

Authors:  J W Smith; T L McDonald
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.